Over-expression of mir-124 inhibits MMP-9 expression and decreases invasion of renal cell carcinoma cells.

CONCLUSIONS: MiR-124 down-regulation was associated with renal cancer cell OS-RC-2 invasion enhancement. Over-expression of miR-124 attenuated OS-RC-2 cell invasion by down-regulating STAT3 and MMP-9. PMID: 30338828 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Related Links:

ConclusionTP53 mutations are potential prognostic markers that can be used to further improve the accuracy of predicting survival and disease-free survival times of cancer patients.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Dr. Brian Rini and Dr. David F. McDermott discuss two different clinical trials for #KidneyCancer patients.12/11/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
Conclusion: HIF-1α C1772T TT genotype and HIF-1α G1790A AA genotype were associated with RCC susceptibility. However, more investigations are required to further clarify the association.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Conclusions: Patients with RCC exhibit differences in such urinary trace elements as Mg, V, Mo, Sn, and Cd with healthy populations, and the discriminant accuracy is high.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Dongyan Hu, Yu Hu, Jisheng Li, Xiuwen WangJournal of Cancer Research and Therapeutics 2018 14(12):1223-1226 Brain metastasis is synchronous to the diagnosis of renal cell carcinoma (RCC). The prognosis of brain metastasis in RCC with the current treatment options is dismissal. Therefore, we present a case of an elderly female patient with RCC showing a partial response of brain metastasis after 18 months of 600 mg once daily sorafenib treatment who underwent right-sided nephrectomy. Further, withdrawal of sorafenib resulted in psychiatric changes along with increased metastasis lesions, which were recovered upon resuming ...
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
RCC is the seventh leading cause of cancer deaths in the U.S. Check out this article for an overview of the condition.12/10/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
ConclusionFor octogenarians with stage 1 renal cell carcinoma, minimally invasive treatments are increasingly utilized, while RN is decreasing. Compared to a younger cohort, a greater proportion of octogenarians are receiving NT. These findings remain encouraging for appropriate treatment of localized disease in patients with advanced age.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
MicroRNAs (miRNAs) serve an important role in renal cancer, but renal cancer miRNA expression data remains inconsistent.12/05/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
Sunitinib treatment has acceptable efficacy and safety profile in Malaysian mRCC patients. The MSKCC and IMDC factors are relevant for predicting survival in our patient cohort while HFS is a promising prognostic predictor which warrants further investigation.12/05/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
We present a comprehensive knowledge of immune therapy through PD-1/PD-L1 blockade that argues how efficient the process is, in colon cancer carcinoma. In this review, we discuss the responsiveness of immunotherapy on PD-1/PD-L1 blockade and various tactics for overcoming weak responses to these checkpoint inhibitors in CRC. More research using controlled trials is required to enable new discoveries to provide continued success with immune-based therapies and grounds for optimism about the future of CRC patients.Graphical abstractThe mechanism of interaction between PD-1+ T-cells and PD-L1/2+ tumor cells.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Kidney Cancer | Renal Cell Carcinoma | Study